Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,439.23
    -1,191.41 (-2.31%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Company News for Jan 23, 2020

Zacks Equity Research

  • Share of Franklin Financial Network, Inc. FSB rose 12.8% after FB Financial Corporation announced a merger with the company

  • Shares of Akcea Therapeutics, Inc. AKCA soared nearly 11% after the company and Ionis reported topline Phase 2 results of AKCEA-APOCIII-L Rx

  • Shares of Ally Financial Inc. ALLY rose 6.8% after the company reported revenues of $1.64 billion for the quarter ending December 2019, surpassing the Zacks Consensus Estimate by 0.4%

  • Shares of Moderna, Inc. MRNA jumped 4.9% after the company reported that it is working with US health agencies to develop a vaccine for Coronavirus



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Franklin Financial Network, Inc. (FSB) : Free Stock Analysis Report
 
Ally Financial Inc. (ALLY) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.